Finance

Lists
A1RG34:BVMF
Argenx Se Bdr
191,57 R$
0,00%
(0,00) 1D
2 ოქტ, 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1RG34...
Open
191,57 R$
High
191,57 R$
Low
191,57 R$
Mkt. cap
58,57 მლრდ.
Avg. vol.
50,00
Volume
90,00
52-wk high
213,15 R$
52-wk low
143,22 R$
Shares outstanding
62,56 მლნ.
No. of employees
2 ათ.
Open
191,57 R$
High
191,57 R$
Low
191,57 R$
Mkt. cap
58,57 მლრდ.
Avg. vol.
50,00
Volume
90,00
52-wk high
213,15 R$
52-wk low
143,22 R$
Shares outstanding
62,56 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
CEO-
Employees1,86 ათ.
Founded25 აპრ. 2008
Headquarters-
Sector-
Websiteargenx.com
Last report
23 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
7,32 US$ / 6,52 US$
+12,32%beat
Revenue / Est. (USD)
1,54 მლრდ. / 1,44 მლრდ.
+6,82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,15 მლრდ.
1,31 მლრდ.
1,31 მლრდ.
1,54 მლრდ.
Cost of goods sold
465,08 მლნ.
521,40 მლნ.
564,00 მლნ.
631,00 მლნ.
Cost of revenue
465,08 მლნ.
521,40 მლნ.
564,00 მლნ.
631,00 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336,29 მლნ.
429,62 მლნ.
355,00 მლნ.
417,00 მლნ.
Operating expense
336,29 მლნ.
429,62 მლნ.
355,00 მლნ.
417,00 მლნ.
Total operating expenses
801,37 მლნ.
951,02 მლნ.
919,00 მლნ.
1,05 მლრდ.
Operating income
349,97 მლნ.
359,56 მლნ.
394,00 მლნ.
493,00 მლნ.
Other non operating income
-
-907,00 ათ.
-
-1,00 მლნ.
EBT including unusual items
386,05 მლნ.
403,29 მლნ.
426,00 მლნ.
531,00 მლნ.
EBT excluding unusual items
386,05 მლნ.
391,71 მლნ.
426,00 მლნ.
531,00 მლნ.
Income tax expense
41,80 მლნ.
-129,66 მლნ.
60,00 მლნ.
59,00 მლნ.
Effective tax rate
10,83%
-32,15%
14,08%
11,11%
Other operating expenses
-
-
-
-
Net income
344,26 მლნ.
532,95 მლნ.
366,00 მლნ.
472,00 მლნ.
Net profit margin
29,90%
40,67%
27,88%
30,63%
Earnings per share
5,18
8,02
5,52
7,32
Interest and investment income
42,70 მლნ.
44,95 მლნ.
44,00 მლნ.
48,00 მლნ.
Interest expense
-993,00 ათ.
-
-1,00 მლნ.
-1,00 მლნ.
Net interest expenses
41,71 მლნ.
44,95 მლნ.
43,00 მლნ.
47,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
350,35 მლნ.
361,38 მლნ.
395,82 მლნ.
501,50 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები